Axovant Gene Therapies Ltd (AXGT)

[senderos]

Started studying this one today. The company has a huge amount of cash (about $230M), which I assume they raised when they were selling their stock at about $25 per share. But their lead drug has been shut down, which only leaves one other drug in the pipeline. I like that fact that it is beaten down and cheap, with lots of cash, but what future catalysts are there in the short term? Any ideas?

I assume that with all that cash, they may just buy another drug from a big company and start developing it, just as they did with their lead drug that failed its trials.